ZOMETA® |4Mg Dosing & Administration For Bone Metastases And Tumour-Induced Hypercalcaemia (TIH)
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano

Left Nav Search
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics 		 
ZOMETA dosing and administration for TIH Handle with ZOMETA



Treat tumour-induced hypercalcaemia with ZOMETA® 4 mg

  • For patients with TIH, the recommended dose of ZOMETA is 4 mg1
  • ZOMETA 4 mg should be reconstituted and further diluted with 100 mL 0.9% w/v sodium chloride or 5% w/v glucose solution1
  • ZOMETA should be infused over no less than 15 minutes1
 

Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About ZOMETA | ZOMETA Patient Case Studies | ZOMETA Dosing & Administration | ZOMETA Safety & Tolerability | ZOMETA Clinical News | ZOMETA For Your Patients | Professional Resource Center
ZOMETA Around the World

About Novartis OncologyZometa Site MapZometa ContactZOMETA Privacy
 


Use of this website is subject to our Terms of Use
© 2010 Novartis AG.